Methadone in THA for Post-op Pain and Opioid Reduction
Reduction of Post-op Pain and Opioid Consumption With the Addition of Methadone in Total Hip Arthroplasty: a Double-blind Randomized Control Trial
Medical University of South Carolina
162 participants
Jan 12, 2026
INTERVENTIONAL
Conditions
Summary
This randomized, double-blind controlled trial investigates whether intraoperative intravenous methadone (0.15 mg/kg based on ideal body weight) reduces acute postoperative pain and opioid consumption in patients undergoing elective total hip arthroplasty under spinal anesthesia with mepivacaine. The primary outcome is patient-reported pain on a visual analog scale (VAS) 30-60 minutes after arrival in the post-anesthesia care unit (PACU). Secondary outcomes include opioid use, pain scores over time, incidence of nausea/vomiting, and quality of recovery. A total of 162 subjects will be enrolled at MUSC surgical sites.
Eligibility
Inclusion Criteria11
- Inclusion
- Ages 18-75 years of age
- Undergoing elective primary total hip arthroplasty with mepivacaine in the spinal anesthesia
- Exclusion
- Allergy to methadone or mepivacaine
- Severe liver disease defined as Child's Pugh Class C
- End stage renal disease requiring dialysis
- Known diagnosis of prolonged QT syndrome
- Currently pregnant
- Unable to provide written, informed consent
- Non-English speaking
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will intraoperatively receive methadone 0.15mg/kg IV, based on ideal body weight.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07227064